Trial Comparing Niraparib-bevacizumab-TSR042 and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Condition: Ovarian Cancer Interventions: Drug: Niraparib; Drug: Bevacizumab; Drug: TSR042; Drug: Carboplatin; Drug: Paclitaxel Sponsor: Nordic Society for Gynaecologic Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials